Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

and advanced cervical cancer. In the?US, the generic name for Libtayo in its approved?indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of ...

This positive news in skin cancer is notable for several reasons: LIBTAYO gained FDA approval in 2018 for CSCC and has also been approved to treat non-small cell lung cancer (NSCLC) as well.

CSCC is the second most common type of skin cancer, with approximately 1.8 million cases diagnosed in the US every year. Libtayo is designed to block cancer cells from using the PD-1 pathway to ...